血管紧张素II用于分布性休克管理的专家共识声明
该共识由意大利重症医学专家组采用改良德尔菲技术制定,围绕5个临床问题形成17条声明,共识定义为≥75%受访者评分落在1-3(不同意)或7-9(同意)的3分区间内。最终13条声明达成同意共识,涵盖难治性休克联合不同机制药物的可能性、血管紧张素II减少血管升压药抵抗性脓毒性休克儿茶酚胺需求的效用、肾素浓度可用于识别最可能获益患者,以及血管紧张素II使用的潜在障碍。专家组认为血管紧张素II是减少血管升压药抵抗性脓毒性休克儿茶酚胺需求的有用治疗,同时指出需要额外临床试验进一步阐明其疗效与安全性,并研究其潜在作用机制及优化难治性分布性休克的治疗方案。
要点
- 专家组达成共识:血管紧张素II被认为是减少血管升压药抵抗性脓毒性休克儿茶酚胺需求的有用治疗。
- 共识认为肾素浓度可用于识别最可能从血管紧张素II恢复血管张力中获益的患者。
- 共识同意可评估在难治性休克治疗中加入不同作用机制药物的可能性。
- 共识同意血管紧张素II对血管紧张素转化酶活性降低或被药物阻断的患者有效。
- 专家组指出需要额外临床试验进一步阐明血管紧张素II的疗效与安全性,并研究其潜在作用机制及优化难治性分布性休克的治疗方案。
适用人群与场景
- 分布性休克患者,尤其是血管升压药抵抗性脓毒性休克患者。
- 血管紧张素转化酶活性降低或被药物阻断的患者。
- 可能从血管紧张素II恢复血管张力中获益的患者,可通过肾素浓度识别。
诊断标准与关键阈值
- 共识达成标准:≥75%的受访者评分落在1-3分(不同意)或7-9分(同意)的3分区间内。
处置流程与药物剂量
- 专家组同意可评估在难治性休克治疗中加入不同作用机制药物的可能性。
- 专家组同意血管紧张素II可用于减少血管升压药抵抗性脓毒性休克患者的儿茶酚胺需求。
- 专家组认为肾素浓度可用于识别最可能从血管紧张素II恢复血管张力中获益的患者。
研究设计与关键结果
- 专家组通过在线范围界定研讨会确定5个临床问题,基于文献回顾和临床经验形成20条声明,经两名协调员筛选后最终17条声明进入在线调查。
- 17条声明中13条达成同意共识,定义了现有科学证据的差距、评估难治性休克联合不同机制药物的可能性、血管紧张素II减少血管升压药抵抗性脓毒性休克儿茶酚胺需求的效用,以及血管紧张素II对血管紧张素转化酶活性降低或被药物阻断患者的有效性。
- 共识广泛认为肾素浓度可用于识别最可能从血管紧张素II恢复血管张力中获益的患者,并据此定义了最可能获益的患者人群,同时描述了使用血管紧张素II的一些潜在障碍。
证据类型、等级与局限
- 证据类型:专家共识(改良德尔菲技术)。
- 共识达成标准:≥75%的受访者评分落在1-3分(不同意)或7-9分(同意)的3分区间内。
- 局限:原文未报告局限性。
对床旁实践的改变
- 专家组认为血管紧张素II是减少血管升压药抵抗性脓毒性休克儿茶酚胺需求的有用治疗。
- 专家组认为肾素浓度可用于识别最可能从血管紧张素II恢复血管张力中获益的患者。
- 专家组指出需要额外临床试验进一步阐明血管紧张素II的疗效与安全性,并研究其潜在作用机制及优化难治性分布性休克的治疗方案。
指南或共识出处
- 血管紧张素II用于分布性休克管理的专家共识声明,发表于J Anesth Analg Crit Care。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite the growing body of evidence supporting the use of angiotensin II (ATII) in distributive shock, its integration into existing treatment algorithms requires careful consideration of factors related to patient comorbidities, hemodynamic parameters, cost-effectiveness, and risk-benefit balance. Moreover, several questions regarding its use in clinical practice warrant further investigations. To address these challenges, a group of Italian intensive care specialists (the panel) developed a consensus process using a modified Delphi technique.
METHODS: The panel defined five clinical questions during an online scoping workshop and then provided a short list of statements related to each clinical question based on literature review and clinical experience. A total of 20 statements were collected. Two coordinators screened and selected the final list of statements to be included in the online survey, which consisted of 17 statements. The consensus was reached when ≥ 75% of respondents assigned a score within the 3-point range of 1-3 (disagreement) or 7-9 (agreement).
RESULTS: Overall, a consensus on agreement was reached on 13 statements defining the existing gaps in scientific evidence, the possibility of evaluating the addition of drugs with different mechanisms of action for the treatment of refractory shock, the utility of ATII in reducing the catecholamine requirements in the treatment of vasopressor-resistant septic shock, and the effectiveness of ATII in treating patients in whom angiotensin-converting enzyme activity is reduced or pharmacologically blocked. It was widely shared that renin concentration can be used to identify patients who most likely benefit from ATII to restore vascular tone. Thus, the patients who might benefit most from using ATII were defined. Lastly, some potential barriers to the use of ATII were described.
CONCLUSIONS: ATII was recognized as a useful treatment to reduce catecholamine requirements in treating vasopressor-resistant septic shock. At the same time, the need for additional clinical trials to further elucidate the efficacy and safety of ATII, as well as investigations into potential mechanisms of action and optimization of treatment protocols in patients with refractory distributive shock, emerged.
参考来源
- Landoni G, Cortegiani A, Bignami E, et al. The use of angiotensin II for the management of distributive shock: expert consensus statements. J Anesth Analg Crit Care. 2024. PMID: 39152516. doi:10.1186/s44158-024-00186-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。